KF
PETX

Krilogy Financial’s Aratana Therapeutics, Inc. PETX Stock Holding History

Krilogy Financial’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$1K – 867
2017
Q2 		$1K Buy
+200
New +$1.23K ﹤0.01% 710

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Krilogy Financial's PETX Position: Q3 2017 in Review

Krilogy Financial sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 200 shares — an estimated $1K sold.

Krilogy Financial first reported a position in PETX in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • Krilogy Financial reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Krilogy Financial sold 200 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $1K.
  • Krilogy Financial first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Krilogy Financial's Aratana Therapeutics, Inc. position peaked at $1K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on Krilogy Financial's 13F filing for Q3 2017, filed 15 Nov 2017.